Company: NCEL
Filing Date: 2025-02-25
Form Type: 425
Source: 0001213900-25-016794
Chunk: 0

Company: NewcelX Ltd.
Filing Date: 2025-02-25
Form: 425
Chunk 0
---
Filed by NLS Pharmaceutics Ltd. pursuant to

Rule 425 under the Securities Act of 1933, as amended

Subject Company: Kadimastem Ltd.

<div align='center'>UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of February 2025 (Report No. 2)

Commission file number: 001-39957

NLS PHARMACEUTICS LTD.

(Translation of registrant’s name into English)

The Circle 6

8058 Zurich, Switzerland

(Address of principal executive offices)</div>

Indicate by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.

<div align='center'>Form 20-F ☒ Form
40-F ☐

CONTENTS</div>

On February 25, 2025, NLS Pharmaceutics Ltd., or the Registrant, issued a press release titled: “Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment.” A copy of this press release is furnished herewith as Exhibit 99.1.

<div align='center'>EXHIBIT INDEX</div>

| Exhibit 
 Number  |     | Description of Document                                                                                                                 |
| 99.1    |     | Press release titled: “Kadimastem and iTolerance Successfully Complete Pre-IND Meeting with the FDA for its Type 1 Diabetes Treatment.” |

<div align='center'>1

SIGNATURES</div>

Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.

| Date: February 25, 2025 | NLS Pharmaceutics Ltd. 
 By:                    | /s/ Alexander Zwyer |                         |
|:------------------------|:-----------------------|:--------------------|:------------------------|
|                         |                        | Name:               | Alexander Zwyer         |
|                         |                        | Title:              | Chief Executive Officer |

<div align='center'>2</div>

Exhibit 99.1

<div align='center'>Kadimast